





## **OPPI-QCI Quality Award for Excellent Facility of the year, 2021**

The Award is instituted by OPPI in collaboration with Quality Council of India (QCI) to recognize pharmaceutical facilities excelling in quality manufacturing processes.

Mumbai/Delhi, February 10, 2022: The Organisation of Pharmaceutical Producers of India (OPPI) and Quality Council of India (QCI) today announced the launch of this award at pan-India level, to celebrate excellence in manufacturing processes in pharmaceutical sector.

The award is launched with an intention to help meet the country's agenda of increased manufacturing of pharmaceutical products with best quality at higher volumes at Indian facilities, meeting global manufacturing standards.

**OPPI-QCI Quality Award for Excellent Facility of the year, 2021** highlights the importance of setting and adopting best-in-class global quality standards in the pharmaceutical industry, keeping patient safety at the core. There has been growing awareness in improving and scaling up quality standards for manufacturing facilities in the country.

Commenting on the introduction of the award, Mr. S. Sridhar, President, Organization of Pharmaceutical Producers of India (OPPI) said, "We have seen tremendous advancements in the healthcare and pharmaceutical sector over the past years. To accelerate the momentum and uphold the highest standards of quality in drugs which save lives, OPPI has joined hands with QCI to launch the Quality Award in collaboration with QCI wherein we will encourage large companies, and MSMEs to upgrade significant and innovative practices in manufacturing, thereby facilitating increased global acceptance for the Indian industry".

Commenting on the Quality Award, Mr. C.K. Biswas, CEO, National Board for Quality Promotion, Quality Council of India said, "Quality is imperative in the pharma industry, given the commitment towards patient safety. This award aims to recognize the outstanding achievements by large pharma companies and MSMEs by implementing new technologies, innovative manufacturing systems while following the Good Manufacturing Practices (GMP). Furthermore, with Atmanirbhar Bharat, this award will trigger a manufacturing revitalization of high-quality products in the pharmaceutical industry, thereby facilitating sustainable growth and being the largest exporter in the world."

The awards will be conferred to the winners at the Annual Summit of OPPI, scheduled on 23<sup>rd</sup> and 24<sup>th</sup> March 2022, to be attended by honorable ministers from Government of India and global dignitaries.







To know more about the OPPI-QCI Quality Award for Excellent Facility of the year 2021, please visit the OPPI website: <a href="http://qualityawards.indiaoppi.com">http://qualityawards.indiaoppi.com</a>

\*\*END\*\*

## About OPPI:

The Organisation of Pharmaceutical Producers of India (OPPI) established in 1965, represents the research-based pharmaceutical companies in India. OPPI remains committed to supporting the nation's healthcare objectives and collaborating with all stakeholders to find sustainable solutions. OPPI believes the need for innovation must be balanced with the necessity for more accessible medicines, within a robust IP environment. For more information, please visit <a href="https://www.indiaoppi.com/">https://www.indiaoppi.com/</a>

## About QCI:

Quality Council of India (QCI) was set up in 1997 jointly by the Government of India and the Indian Industry represented by the three premier industry associations i.e. ASSOCHAM, CII and FICCI. QCI has been established to create a mechanism for independent third party assessment of products, services and processes, it operates national accreditation structure and plays a pivotal role at the national level in propagating, adoption and adherence to quality standards in all important spheres of activities. QCI is registered as not-for-profit society with its own Memorandum of Association and Rules & Regulations. For more information, please visit <a href="https://qcin.org/">https://qcin.org/</a>

## Media contacts:

Asawari Sathaye
Director Communications and Patient Advocacy, OPPI
(M):+91-9870095404